Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Inman

Showing results (441-450 of 541) with videos related to

Pageof 55
Sort By:
Annals of the Rheumatic Diseases|February 20, 2014
Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)Joachim Sieper, Jürgen Braun, Jonathan Kay, et al.
Annals of the Rheumatic Diseases|February 7, 2025
Impact of clinical subtype and sex on first-line biologic therapy discontinuation in axial spondyloarthritisPatricia Remalante-Rayco, Emmanuel S Baja, Zeynep Baskurt, et al.
Annals of the Rheumatic Diseases|August 2, 2023
Proteomic and genomic profiling of plasma exosomes from patients with ankylosing spondylitisFataneh Tavasolian, Starlee Lively, Chiara Pastrello, et al.
Annals of the Rheumatic Diseases|May 6, 2009
ARTS1 polymorphisms are associated with ankylosing spondylitis in KoreansChan-Bum Choi, Tae-Hwan Kim, Jae-Bum Jun, et al.
Annals of the Rheumatic Diseases|December 1, 2011
Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE studyJürgen Braun, Xenofon Baraliakos, Kay-Geert A Hermann, et al.
Blood|August 1, 1983
Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpuraJ B Bussel, R P Kimberly, R D Inman, et al.
Expert Opinion on Biological Therapy|January 16, 2008
Antigen-specific therapy of rheumatoid arthritisThomas E Ichim, Xiufen Zheng, Motohiko Suzuki, et al.
Clinical and Experimental Rheumatology|January 7, 2014
Long-term outcome of anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthritisB Hugle, R Burgos-Vargas, R D Inman, et al.
Arthritis Research & Therapy|September 18, 2023
Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III studyXenofon Baraliakos, Désirée van der Heijde, Joachim Sieper, et al.
The Journal of Rheumatology|April 19, 2011
The Spondyloarthritis Research Consortium of Canada registry for spondyloarthritisDafna D Gladman, Proton Rahman, Richard J Cook, et al.
Pageof 55

Showing results (441-450 of 541) with videos related to

Sort By:
Pageof 55
Annals of the Rheumatic Diseases|February 20, 2014
Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)Joachim Sieper, Jürgen Braun, Jonathan Kay, et al.
Annals of the Rheumatic Diseases|February 7, 2025
Impact of clinical subtype and sex on first-line biologic therapy discontinuation in axial spondyloarthritisPatricia Remalante-Rayco, Emmanuel S Baja, Zeynep Baskurt, et al.
Annals of the Rheumatic Diseases|August 2, 2023
Proteomic and genomic profiling of plasma exosomes from patients with ankylosing spondylitisFataneh Tavasolian, Starlee Lively, Chiara Pastrello, et al.
Annals of the Rheumatic Diseases|May 6, 2009
ARTS1 polymorphisms are associated with ankylosing spondylitis in KoreansChan-Bum Choi, Tae-Hwan Kim, Jae-Bum Jun, et al.
Annals of the Rheumatic Diseases|December 1, 2011
Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE studyJürgen Braun, Xenofon Baraliakos, Kay-Geert A Hermann, et al.
Blood|August 1, 1983
Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpuraJ B Bussel, R P Kimberly, R D Inman, et al.
Expert Opinion on Biological Therapy|January 16, 2008
Antigen-specific therapy of rheumatoid arthritisThomas E Ichim, Xiufen Zheng, Motohiko Suzuki, et al.
Clinical and Experimental Rheumatology|January 7, 2014
Long-term outcome of anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthritisB Hugle, R Burgos-Vargas, R D Inman, et al.
Arthritis Research & Therapy|September 18, 2023
Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III studyXenofon Baraliakos, Désirée van der Heijde, Joachim Sieper, et al.
The Journal of Rheumatology|April 19, 2011
The Spondyloarthritis Research Consortium of Canada registry for spondyloarthritisDafna D Gladman, Proton Rahman, Richard J Cook, et al.
Pageof 55